RESEARCH ARTICLE


Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist



Jorge Roig*, 1, Rosana Hernando2, Ramon Mora
1 Servei de Pneumologia, Hospital Nostra Senyora de Meritxell, Escaldes, Andorra, Spain
2 Servei de Pneumologia, Hospital Comarcal Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 265
Abstract HTML Views: 325
PDF Downloads: 146
Total Views/Downloads: 736
Unique Statistics:

Full-Text HTML Views: 159
Abstract HTML Views: 204
PDF Downloads: 117
Total Views/Downloads: 480



© Roig et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Servei de Pneumologia, Hospital Nostra Senyora de Meritxell, AD700 - Escaldes, Andorra, Spain; Fax: +376829627; E-mail: jroig@separ.es


Abstract

In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full β2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability.

Keywords: Indacaterol, tachyphylaxis, activity profile, safety..